Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Compound of prostate stem cell antigen polypeptide and nucleic acid and preparation method and application thereof

A stem cell antigen and prostate technology, which is applied in the field of biomedicine to ensure safety, little impact on somatic cells, and improve immunogenicity

Inactive Publication Date: 2013-06-05
THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, how to improve the immunogenicity of these potential targets to break the self-tolerance of tumor antigens is a major problem in the design of tumor vaccines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound of prostate stem cell antigen polypeptide and nucleic acid and preparation method and application thereof
  • Compound of prostate stem cell antigen polypeptide and nucleic acid and preparation method and application thereof
  • Compound of prostate stem cell antigen polypeptide and nucleic acid and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0028] In order to make the object, technical solution and advantages of the present invention clearer, preferred embodiments of the present invention will be described in detail below with reference to the accompanying drawings. The preferred embodiments are only used to illustrate the present invention, rather than limit the present invention, and those skilled in the art can make various equivalent transformations to the technical solutions of the preferred embodiments. The experimental method that does not indicate specific conditions in the preferred embodiment is usually according to conventional conditions, such as described in the Molecular Cloning Experiment Guide (Third Edition, J. Sambrook et al., translated by Huang Peitang, etc., Science Press, 2002) conditions, or as recommended by the manufacturer.

[0029] 1. K 18 -PSCA 14-22 Preparation of / pcDNA3.1(+)-PSCA

[0030] K 18 -PSCA 14-22 The schematic diagram of the construction of / pcDNA3.1(+)-PSCA ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound of PSCA (Prostate Stem Cell Antigen) polypeptide and nucleic acid, which is a granular compound obtained by the way that through positive and negative charge attraction, a PSCA gene recombination eukaryotic expression vector is packaged by fusogenic peptide formed by a positive ion peptide DNA (Deoxyribonucleic Acid) transport carrier and HLA-A2 limit CTL (Cytotoxic T Lymphocyte) epitope peptide PSCA 14-22. The preparation method comprises the steps that in buffer salt solution with pH of 7.2-7.6, the fusogenic peptide and the PSCA gene recombination eukaryotic expression vector are added according to a certain positive and negative charge ratio, are then mixed, and are left standing under room temperature for 0.5-1.5 hours to obtain the compound; the compound is not only combined with the advantages of DNA vaccine and epitope peptide vaccine, but also can imitate natural virus to directly 'infect' APC (Antigen Presenting Cell) and other immune cells, so as to stimulate strong CTL response in vivo. The compound is expected to break down selftolerance of tumour antigen, can be used to prepare prostate cancer therapeutic vaccine of more than 50 % of population in China, and has potential and good development and application prospect in the prostate cancer immunization therapy field.

Description

technical field [0001] The invention belongs to the field of biomedicine, relates to a compound of polypeptide and nucleic acid, and also relates to a preparation method and application of the compound. Background technique [0002] Prostate cancer is one of the malignant tumors that seriously threaten the health of middle-aged and elderly men, and its incidence is increasing year by year, with a high mortality rate, ranking second only to lung cancer. Androgen deprivation therapy has been the standard of care for prostate cancer for more than 50 years; however, most patients eventually develop hormone-resistant prostate cancer (HRPC). For HRPC, there is no effective therapy at present, and the existing treatment methods, including radiotherapy and chemotherapy, cannot prolong the patient's life for more than one year. Therefore, exploring new and effective methods for the treatment of prostate cancer has always been one of the important issues facing clinical urology. [...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/00A61K47/48A61K48/00A61P35/00
Inventor 张克勤李蜀婧刘勇
Owner THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products